Literature DB >> 31772979

A Prospective Evaluation of Acute Toxicity from Proton Therapy for Targets of the Parotid Region.

Roi Dagan1, Curtis M Bryant1, Julie A Bradley1, Daniel J Indelicato1, Michael Rutenberg1, Ronny Rotondo1, Christopher G Morris1, William M Mendenhall1.   

Abstract

PURPOSE: Mucosal toxicities are common acute effects from head-and-neck radiotherapy. The parotid region is ideal for proton therapy (PT) due to sparing radiosensitive tissues distal to the target. We prospectively evaluated acute mucosal toxicity in patients treated with PT for parotid cancers. PATIENTS AND METHODS: Twenty-three patients received primary (n=7) or adjuvant (n=16) PT for parotid cancers, including salivary gland carcinoma (n=17), skin carcinoma with perineural invasion (n=5), and Ewing sarcoma (n=1). PT consisted of 2-3 passively scattered fields. Median dose was 70 Gy (RBE) (range, 55.8-74.4) using various fractionation schedules. Seven patients received concurrent chemotherapy. Acute toxicities, nutritional status, and weight were prospectively evaluated weekly.
RESULTS: Most patients experienced no or minimal toxicity throughout therapy. There were no grade 4 toxicities and only 1 transient grade 3 dysphagia. At the end of treatment, the worst mucositis was grade 2 in 35% with 43% experiencing no mucositis; the worst dysphagia was grade 2 in 26 % with 48% having no dysphagia; the worst dysgeusia was grade 2 in 23% with 50% experiencing no dysgeusia; and the worst xerostomia was grade 2 in 14% with 23% experiencing no xerostomia. The median weight loss was 3%. No patient required a feeding tube or intermittent intravenous hydration.
CONCLUSIONS: PT for tumors of the parotid region results in very low rates of mucosal toxicity. Nutritional status and weight were preserved throughout therapy. These results should be validated with patient-reported outcomes, and their impact on functional recovery and treatment costs remain unexplored. © Copyright 2016 International Journal of Particle Therapy.

Entities:  

Keywords:  gastrointestinal; head and neck; outcomes; toxicity

Year:  2016        PMID: 31772979      PMCID: PMC6871618          DOI: 10.14338/IJPT-16-00010.2

Source DB:  PubMed          Journal:  Int J Part Ther        ISSN: 2331-5180


  7 in total

1.  Postoperative radiotherapy for malignant tumors of the parotid gland.

Authors:  A S Garden; A K el-Naggar; W H Morrison; D L Callender; K K Ang; L J Peters
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-01       Impact factor: 7.038

2.  Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation.

Authors:  Paul B Romesser; Oren Cahlon; Eli Scher; Ying Zhou; Sean L Berry; Alisa Rybkin; Kevin M Sine; Shikui Tang; Eric J Sherman; Richard Wong; Nancy Y Lee
Journal:  Radiother Oncol       Date:  2016-02-08       Impact factor: 6.280

3.  Long-term outcomes and quality of life of 186 patients with primary parotid carcinoma treated with surgery and radiotherapy at the Daniel den Hoed Cancer Center.

Authors:  Abrahim Al-Mamgani; Peter van Rooij; Gerda M Verduijn; Cees A Meeuwis; Peter C Levendag
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

4.  Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group.

Authors:  Chris H J Terhaard; H Lubsen; I Van der Tweel; F J M Hilgers; W M H Eijkenboom; H A M Marres; R E Tjho-Heslinga; J M A de Jong; J L N Roodenburg
Journal:  Head Neck       Date:  2004-08       Impact factor: 3.147

5.  Malignant tumors of major salivary gland origin. A matched-pair analysis of the role of combined surgery and postoperative radiotherapy.

Authors:  J G Armstrong; L B Harrison; R H Spiro; D E Fass; E W Strong; Z Y Fuks
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-03

6.  Association of Body Composition With Survival and Locoregional Control of Radiotherapy-Treated Head and Neck Squamous Cell Carcinoma.

Authors:  Aaron J Grossberg; Sasikarn Chamchod; Clifton D Fuller; Abdallah S R Mohamed; Jolien Heukelom; Hillary Eichelberger; Michael E Kantor; Katherine A Hutcheson; G Brandon Gunn; Adam S Garden; Steven Frank; Jack Phan; Beth Beadle; Heath D Skinner; William H Morrison; David I Rosenthal
Journal:  JAMA Oncol       Date:  2016-06-01       Impact factor: 31.777

7.  Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years' experience at the European Institute of Oncology.

Authors:  Daniela Alterio; Barbara A Jereczek-Fossa; Mara Griseri; Alberto D'Onofrio; Gioacchino Giugliano; Maria R Fiore; Viviana Vitolo; Piero Fossati; Gaia Piperno; Luca S Calabrese; Elena Verri; Fausto G Chiesa; Roberto Orecchia
Journal:  Tumori       Date:  2011 May-Jun
  7 in total
  3 in total

Review 1.  Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges.

Authors:  Sandra Nuyts; Heleen Bollen; Sweet Ping Ng; June Corry; Avraham Eisbruch; William M Mendenhall; Robert Smee; Primoz Strojan; Wai Tong Ng; Alfio Ferlito
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

2.  Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers.

Authors:  Robert H Press; Richard L Bakst; Sonam Sharma; Rafi Kabarriti; Madhur K Garg; Brian Yeh; Daphna Y Gelbum; Shaakir Hasan; J Isabelle Choi; Chris A Barker; Arpit M Chhabra; Charles B Simone; Nancy Y Lee
Journal:  Int J Part Ther       Date:  2021-06-25

3.  Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes.

Authors:  Alexander N Hanania; Xiaodong Zhang; G Brandon Gunn; David I Rosenthal; Adam S Garden; C David Fuller; Jack Phan; Jay P Reddy; Amy Moreno; Gregory Chronowski; Shalin Shah; Noveen Ausat; Ehab Hanna; Renata Ferrarotto; Steven J Frank
Journal:  Int J Part Ther       Date:  2021-06-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.